v3.25.2
SCHEDULE OF POTENTIALLY DILUTIVE SECURITIES WERE EXCLUDED FROM CALCULATION OF DILUTED NET LOSS PER SHARE (Details) - shares
 3 Months Ended 6 Months Ended
Jun. 30, 2025
Jun. 30, 2024
Jun. 30, 2025
Jun. 30, 2024
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]        
Total potentially dilutive shares 6,180,000 1,710,000 6,180,000 1,710,000
Options To Purchase Shares Of Common Stock [Member]        
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]        
Total potentially dilutive shares 120,000 120,000 120,000 120,000
Warrants To Purchase Shares Of Common Stock [Member]        
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]        
Total potentially dilutive shares 4,960,000 490,000 4,960,000 490,000
Warrants To Purchase Shares Of Common Stock [Member] | CreoMed Inc [Member] | February 14, 2021 [Member]        
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]        
Total potentially dilutive shares [1] 400,000 400,000 400,000 400,000
Warrants To Purchase Shares Of Common Stock [Member] | CreoMed Inc [Member] | April 1, 2022 [Member]        
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]        
Total potentially dilutive shares 400,000 400,000 400,000 400,000
Warrants To Purchase Shares Of Common Stock [Member] | Demir Bingol [Member] | March 16, 2021 [Member]        
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]        
Total potentially dilutive shares [1] 300,000 300,000 300,000 300,000
[1] The Company has cancelled and regranted these warrants to purchase 1,098,830 shares (698,830 warrants issued to the Ahmet Demir Bingol and 400,000 to CreoMed Inc.) of the Company’s common stock on June 29, 2021 in conjunction with the share exchange agreement.